4 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $81M | -$143M | 92.9% | -149.3% | -$141M | — | $261M |
| 2024 | $71M | -$158M | 91.6% | -184.4% | -$125M | — | $251M |
| 2023 | $70M | -$240M | 96.4% | -238.6% | -$122M | — | $279M |
| 2022 | $210M | -$157M | 98.4% | -58.8% | -$139M | — | $326M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $20M | -$33M | 0.0% | -126.0% | -$30M | — | $231M |
| Dec '25 | — | -$6M | — | — | -$31M | — | $261M |
| Sep '25 | $16M | -$41M | 0.0% | -196.6% | -$30M | — | $235M |
| Jun '25 | $18M | -$57M | 0.0% | -244.1% | -$24M | — | $265M |
| Mar '25 | $17M | -$39M | 0.0% | -163.5% | -$57M | — | $195M |
| Dec '24 | — | -$31M | — | — | -$22M | — | $251M |
| Sep '24 | $18M | -$44M | 0.0% | -197.4% | -$25M | — | $274M |
| Jun '24 | $17M | -$37M | 0.0% | -170.5% | -$33M | — | $300M |
| Mar '24 | $18M | -$47M | 0.0% | -188.3% | -$45M | — | $234M |
| Dec '23 | — | -$85M | — | — | -$32M | — | $279M |
| Sep '23 | $14M | -$47M | 0.0% | -253.4% | -$37M | — | — |
| Jun '23 | $19M | -$49M | 0.0% | -206.5% | -$36M | — | — |
| Mar '23 | $19M | -$59M | 0.0% | -264.9% | -$16M | — | — |
How the market has priced ADCT against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 3 years, ADC Therapeutics SA's revenue has declined 27.1% per year. These are computed facts, not advice.
As of FY2025, ADC Therapeutics SA reported — of total debt against $261M of cash; operating income covered interest expense -2.4×.
In FY2025, gross margin was 92.9%, operating margin -149.3%, and net margin -175.3%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.